Investors focused on the Medical space have likely heard of Vertex Pharmaceuticals (VRTX), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Vertex Pharmaceuticals is one of 931 individual stocks in the Medical sector. Collectively, these companies sit at #13 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. VRTX is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for VRTX's full-year earnings has moved 16.05% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that VRTX has returned about 0.71% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 0.21% on average. This shows that Vertex Pharmaceuticals is outperforming its peers so far this year.
Looking more specifically, VRTX belongs to the Medical - Biomedical and Genetics industry, a group that includes 414 individual stocks and currently sits at #177 in the Zacks Industry Rank. On average, this group has lost an average of 1.08% so far this year, meaning that VRTX is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track VRTX. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Outperforming%20Other%20Medical%20Stocks%20This%20Year%3F%20%7C%20Nasdaq&_biz_n=7&rnd=958959&cdn_o=a&_biz_z=1743187331209)
%20Outperforming%20Other%20Medical%20Stocks%20This%20Year%3F%20%7C%20Nasdaq&rnd=399570&cdn_o=a&_biz_z=1743187331214)